Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.


CSE:SONA - Post by User

Comment by MikeyHon Apr 06, 2021 7:35am
142 Views
Post# 32940074

RE:RE:Soon folks...I hope

RE:RE:Soon folks...I hopeBut all the news that came before Regan took over was over-hyped BS.

1) GE Healthcare 'partnership' (gone nowhere)
2) Test 'validation' (External LoD run - no clinical data or validation)
3) Saudi clinical studies (weak clinical data that highlights just how average the test is in a pathetic 99 samples)
4) Overconfident regulatory submissions (we all know how that ended)

The stock's wild ride has all been a consequence of the company's BS pumped NRs, and gullible investors believing it. Maybe folks are starting to realize this finally

Armydoc - so were you pleased with the quarterly fins?
<< Previous
Bullboard Posts
Next >>